AVI stock loses nearly third of value after new eteplirsen data
This article was originally published in Scrip
Executive Summary
AVI BioPharma announced positive results for its drug to treat Duchenne muscular dystrophy (DMD) as the stock market opened on 2 April, but the Bothell, Washington-based biotechnology company's share price still dropped almost 30% to close at $1.08.